CRBU, Caribou Biosciences, Inc

"Loading Stock Price & Valuation Data ..."

Agentic AI (Pro) Picks for CRBU

Subscribe to iPick.ai (Pro) to use Power Picks, Hidden-Gem Picks, and more.


News Summary: Subscribe

Unlock News Summary by Subscribing to iPick.ai Premium!





Unlock Ask CRBU by Subscribing to iPick.ai Premium!



Stock Chart




Latest YouTube Video:

Please Login/Register (click on the top-right button) to see the latest video on CRBU, Caribou Biosciences, Inc.

CEO:Dr. Rachel E. Haurwitz Ph.D.

Headquarter: 2929 7th Street, Suite 105, Berkeley, CA, United States, 94710

Industry: Biotechnology,   Employees: 147

Business Summary

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.